TELO
Telomir Pharmaceuticals, Inc.Company Information
- Company Name
- Telomir Pharmaceuticals, Inc.
- CIK
- CIK0001971532
- Category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- Ticker: Exchange
- TELO: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- TELO
SEC filing data through
Insider Sentiment
- Last purchase
- 2024-02-13
- Last sale
- 2024-08-19
- Shares purchased (TTM)
- 138,000
- Shares sold (TTM)
- 400
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 2,947,502
- Shares outstanding
- 60,837,460
- Ownership
- 4.84%
Earnings Market Reaction
- Filing date
- 2026-08-13
- Price on filing date
- —
- 1-month reaction
- 10.48%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | |||||||||||||||||
| Cash | 5 | 6 | 7 | 7 | 1 | 0 | 1 | 1 | 2 | 3 | 0 | ||||||
| Deferred Offering Costs | - | - | - | - | - | - | - | - | - | - | 0 | ||||||
| Prepaid Expense Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Other Receivables | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | ||||||
| Other Receivables Net Current | - | - | - | - | - | - | - | - | - | - | 0 | ||||||
| Assets Current | 5 | 6 | 7 | 7 | 1 | 0 | 1 | 1 | 2 | 4 | 0 | ||||||
| Deferred Costs | - | - | - | - | - | - | - | - | - | - | 4 | ||||||
| Assets | 5 | 6 | 7 | 7 | 1 | 0 | 1 | 1 | 2 | 4 | 5 | ||||||
Liabilities Current | |||||||||||||||||
| Accounts Payable And Accrued Liabilities Current | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 1 | ||||||
| Other Liabilities | - | - | - | - | - | - | - | 0 | 0 | 0 | 1 | ||||||
| Lines Of Credit Current | - | - | - | - | - | - | - | - | - | - | 0 | ||||||
| Loans Payable Current | 0 | 0 | - | - | - | - | - | - | - | - | - | ||||||
| Other Liabilities Current | - | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - | 1 | ||||||
| Liabilities Current | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | ||||||
| Liabilities | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | ||||||
Stockholders Equity | |||||||||||||||||
| Additional Paid In Capital | 49 | 47 | 47 | 46 | 38 | 33 | 31 | 28 | 23 | 23 | 18 | ||||||
| Retained Earnings Accumulated Deficit | -44 | -42 | -41 | -39 | -38 | -33 | -31 | -28 | -22 | -20 | -14 | ||||||
| Stockholders Equity | 5 | 5 | 6 | 7 | 0 | -0 | 1 | 0 | 2 | 3 | 3 | ||||||
| Liabilities And Stockholders Equity | 5 | 6 | 7 | 7 | 1 | 0 | 1 | 1 | 2 | 4 | 5 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | ||||||
| Common Stock Shares Issued | 69 | 34 | 34 | 34 | 31 | 30 | 30 | 30 | 30 | 30 | 29 | ||||||
| Shares Outstanding | 69 | 34 | 34 | 34 | 31 | 30 | 30 | 30 | 30 | 30 | 29 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialTelomir Pharmaceuticals, Inc. (TELO) — SEC Financial Statements & Analysis
Telomir Pharmaceuticals, Inc. (TELO) is a pharmaceutical preparations company, incorporated in FL. Telomir Pharmaceuticals, Inc. trades on Nasdaq as: TELO. Telomir Pharmaceuticals, Inc. (TELO)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13. Based on that filing, Telomir Pharmaceuticals, Inc. carries a market cap of $77.87M, a P/E ratio of -13.25x, a P/B ratio of 15.47x, an enterprise value of $72.84M, and an EV/EBITDA multiple of -12.38x. On profitability, it posts a Return on Equity (ROE) of -213.10% and a Return on Assets (ROA) of -189.68%. Per share, it reports EPS of $-0.10, diluted EPS of $-0.10, free cash flow per share of $-0.08, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of -63.46% year-over-year and EPS growth of -81.97% year-over-year. On the balance sheet, it maintains a current ratio of 16.14x, a quick ratio of 15.55x, working capital of $5.03M, a debt-to-equity ratio of 0.07x, a debt ratio of 0.06, an interest coverage ratio of -1037.14x, free cash flow of $-4.91M (TTM), and net debt of $-5.03M. Figures sourced from SEC EDGAR.
- Market Cap
- $77.87M
- P/E TTM
- -13.25x
- EPS TTM
- $-0.10
- P/B TTM
- 15.47x
- ROE TTM
- -213.10%
- ROA TTM
- -189.68%
- Debt To Equity
- 0.07x
- Free Cash Flow TTM
- $-4.91M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Telomir Pharmaceuticals, Inc. in?
Telomir Pharmaceuticals, Inc. (TELO) operates in the Pharmaceutical Preparations industry.
What exchange does TELO trade on?
Telomir Pharmaceuticals, Inc. (TELO) trades on the Nasdaq.
Where is Telomir Pharmaceuticals, Inc. incorporated?
Telomir Pharmaceuticals, Inc. is incorporated in FL.
When was Telomir Pharmaceuticals, Inc. (TELO)'s most recent SEC filing?
Telomir Pharmaceuticals, Inc. (TELO)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13.
What is TELO's market cap?
Telomir Pharmaceuticals, Inc. (TELO) has a market capitalization of $77.87M as of 2026-06-30.
What is TELO's EPS (earnings per share)?
Telomir Pharmaceuticals, Inc. (TELO)'s trailing twelve month EPS is $-0.10 as of 2026-06-30.
What is TELO's ROE (return on equity)?
Telomir Pharmaceuticals, Inc. (TELO)'s trailing twelve month Return on Equity (ROE) is -213.10% as of 2026-06-30.
What is TELO's ROA (return on assets)?
Telomir Pharmaceuticals, Inc. (TELO)'s trailing twelve month Return on Assets (ROA) is -189.68% as of 2026-06-30.
What is TELO's EV/EBITDA?
Telomir Pharmaceuticals, Inc. (TELO)'s trailing twelve month EV/EBITDA is -12.38x as of 2026-06-30.